1Lee WM. Hepatitis B virus infection. N Engl J Med, 1997, 337(24): 1733 - 1745.
2Krogsgaard K.The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat, 1998,5(6):389 ～ 397.
3Farrell GC. Clinical potential of emerging new agents in hepatitis B. Drugs, 2000, 60(4): 701 ～ 710.
4Guan R, Lai CL, Liaw YF, et al. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J Gastroenter Hepat,2001, 16(Suppl): A60 ～ 61.
5Lai CL, Yuen MF. Profound suppression of hepatitis B virus replication with lamivudine. J Med Virol, 2000,61(3): 367 ～373.
6Schiff ER. Lamivudine for hepatitis B in clinical practice. J Med Virol, 2000, 61 (3): 386 - 391.
7Fontana RJ. Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when? J Hepatol, 2000,33(2): 329 ～ 332.
8Yao-FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatology, 2000, 33(2): 301 ～ 307.
9Dan YY, Lee MM, Lim LL, et al. Clinical pathogenicity of lamivudine resistant hepatitis B virus (HBV) is related to the pre-treatment (wildtype) status.J Gastroenter Hepat, 2001, 16(Suppl): A56～57.
10BAncell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm, 2001, 58(10):879-885; quiz 886 - 888.
9Zoulim F. Antiviral therapy of chronic hepatitis B:can we clear The virus and prevent drug resistance? [J]. Antivir Chem Chemother her,2004,15 (6) : 299-305.
10Chan HL,Leung NW,Hui AY. A randomized,controlledtrial of combination therapy for chronic hepatitis B:comparing pegylated interferon2alpha 2b and lamivudine with lamivudinealone[J]. Ann Intern Med,2005,142 (4) : 240-250.
